DexCom IncDXCM

DXCM current price
$72.70-28.29%

Capital at risk.

1W
+5.16%
1M
+5.39%
3M
+3.78%
6M
-43.95%
1Y
-28.29%
MAX
+461.82%
About DexCom Inc
Ticker
info
DXCM
Trading on
info
NASDAQ
ISIN
info
US2521311074
Industry
info
Medical Devices
Sector
info
Healthcare
CEO
info
Kevin Ronald Sayer
Headquarters
info
6340 Sequence Drive, San Diego, CA, United States, 92121
Employees
info
9,500
Website
info
dexcom.com
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Metrics
BasicAdvanced
Market cap
info
$29B
P/E ratio
info
45.05
EPS
info
$1.65
Dividend Yield
info
0.00%
Beta
info
1.17
Forward P/E ratio
info
34.25
EBIDTA
info
$840M
Ex dividend date
info
-
Price & volume
Market cap
info
$29B
Average daily volume
info
4.8M
90-day return
info
3.78%
30-day return
info
5.39%
7-day return
info
5.16%
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
45.05
Forward P/E
info
34.25
PEG ratio
info
1.1
Trailing P/E
info
45.05
Price to sales
info
7.34
Price to book
info
13.88
Earnings
EPS
info
$1.65
EPS estimate (current quarter)
info
$0.43
EPS estimate (next quarter)
info
$0.52
EBITDA
info
$840M
Revenues (TTM)
info
$3.95B
Revenues per share (TTM)
info
$10.09
Technicals
Beta
info
1.17
52-week High
info
$142.00
52-week Low
info
$62.34
50-day moving average
info
$69.72
200-day moving average
info
$103.36
Short ratio
info
1.83
Short %
info
2.23%
Management effectiveness
ROE (TTM)
info
32.06%
ROA (TTM)
info
6.06%
Profit margin
info
17.22%
Gross profit margin
info
$1.88B
Operating margin
info
15.29%
Growth
Quarterly earnings growth (YoY)
info
15.70%
Quarterly revenue growth (YoY)
info
2.00%
Share stats
Outstanding Shares
info
391M
Float
info
388M
Insiders %
info
0.32%
Institutions %
info
100.93%
Analyst Insights & forecasts
info

80% Buy

20% Hold

0% Sell

Based on information from 25 analysts.

Average price target

info
$95.97
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
$0.50
$0.43
16.28%
Q4 • 23Beat
$0.32
$0.27
18.52%
Q1 • 24Beat
$0.43
$0.39
10.26%
Q2 • 24Beat
$0.45
$0.44
2.27%
Q3 • 24Beat
-
$0.52
-
Q4 • 24Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$1B
$144M
14.29%
Q2 • 24
$994M
$135M
13.54%
Q3 • 24
1.01%
6.20%
5.25%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$6.8B
$4.36B
64.20%
Q2 • 24
$6.35B
$4.37B
68.85%
Q3 • 24
6.55%
0.23%
7.25%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$279M
$-189M
$-1.4M
$213M
Q2 • 24
$200M
-
$-737M
$88.3M
Q3 • 24
28.60%
-
52,507.14%
58.60%
QoQ growth
QuarterlyAnnual
Sentiment analysis

-1.5

Neutral

+1.5

0.08

Last 30 days

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a DexCom Inc share?
Collapse

DexCom Inc shares are currently traded for $72.70 per share.

How many shares does DexCom Inc have?
Collapse

DexCom Inc currently has 391M shares.

Does DexCom Inc pay dividends?
Collapse

No, DexCom Inc doesn't pay dividends.

What is DexCom Inc 52 week high?
Collapse

DexCom Inc 52 week high is $142.00.

What is DexCom Inc 52 week low?
Collapse

DexCom Inc 52 week low is $62.34.

What is the 200-day moving average of DexCom Inc?
Collapse

DexCom Inc 200-day moving average is $103.36.

Who is DexCom Inc CEO?
Collapse

The CEO of DexCom Inc is Kevin Ronald Sayer.

How many employees DexCom Inc has?
Collapse

DexCom Inc has 9,500 employees.

What is the market cap of DexCom Inc?
Collapse

The market cap of DexCom Inc is $29B.

What is the P/E of DexCom Inc?
Collapse

The current P/E of DexCom Inc is 45.05.

What is the EPS of DexCom Inc?
Collapse

The EPS of DexCom Inc is $1.65.

What is the PEG Ratio of DexCom Inc?
Collapse

The PEG Ration of DexCom Inc is 1.1.

What do analysts say about DexCom Inc?
Collapse

According to the analysts DexCom Inc is considered a buy.